SEP-363856

Unassigned

New Medicines

Schizophrenia

Information

New molecular entity
Sunovion
Sunovion

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Serotonin-1A-receptor-agonist (5-HT1A) and trace amine-associated receptor 1 agonist (TAAR1).
An English study reported an incidence of 15.2 per 100,000 person-years. A systematic review reported a prevalence of 7.2 per 1,000 persons. In children and adolescents between the ages of 5 and 18 the prevalence has been estimated to be 0.4% [1].
Schizophrenia
Oral